Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 146 clinical trials
Clinical Trial To Evaluate Safety And Efficacy Of US-APR2020 In Subjects With Chronic Kidney Disease Stage IV (CKD)

The aim of this Phase 2 study is to evaluate the safety and efficacy of the live biotherapeutic product, US-APR2020, in the management of patients with CKD Stage IV.

  • 20 Apr, 2022
Twice Against Thrice-weekly Hemodialysis (TATH)

Hemodialysis is the most worldwide prescribed renal replacement therapy for patients with end-stage renal disease. The frequency of sessions per week remains a debatable issue. In the majority of developed Western and Asian countries, patients on chronic hemodialysis are undergoing three dialysis sessions weekly. In developing countries and some developed …

renal replacement therapy
chronic hemodialysis
chronic renal failure
  • 26 Feb, 2022
  • 1 location
Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR) (BELACOEUR)

risk factors for progression to CKD are advanced age, pre-transplantation CKD, degradation of glomerular filtration rate (GFR) in the first year post-transplantation, and nephrotoxicity of calcineurin

  • 13 Apr, 2022
  • 5 locations
TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients (INTERCEPT)

months. Protocol kidney graft biopsies will be performed at baseline, at 12 and 24 months. The primary outcome is the mean rate of change in graft function as assessed by estimated glomerular filtration

  • 22 Mar, 2022
Viral Load Guided Immunosuppression After Lung Transplantation

(TTV viral load in whole blood) compared to conventional calcineurin inhibitor dosing. Indicator for toxicity will be the glomerular filtration rate (GFR), which will be estimated using the CKD-EPI

  • 03 Jun, 2021
  • 2 locations
Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy

The study was a 48-week multicenter, randomized, double-blind, placebo-controlled trial that included 8 weeks of pre-screening and lifestyle education, 32 weeks of treatment, and 16 weeks of follow-up.To observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion in Chinese patients with type 2 diabetic nephropathy who received …

  • 27 Jan, 2021
  • 1 location
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy in subjects who previously experienced liver chemistry test abnormalities while treated with tolvaptan and were permanently discontinued from the drug for that reason. Up to 50 eligible subjects will be enrolled and treated …

chronic kidney disease
body mass index
renal disease
  • 03 May, 2021
  • 9 locations
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS)

An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care

  • 02 May, 2022
  • 9 locations
CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients

This is a Phase II/III, Single-center, Prospective, Open-label, Single Arm Study of 30 Simultaneous Kidney Pancreas recipients who received a transplant at least 3 months, but no more than 5 years prior, with a history of tremors following transplantation.

  • 21 Apr, 2022
  • 1 location
Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy

The purpose of this study is to evaluate the efficacy and safety of intramuscular (IM) administration of Engensis on pain in participants with painful diabetic peripheral neuropathy (DPN) in the feet and lower legs, as compared to Placebo, as a second Phase 3, well controlled study, sufficient in supporting the …

peripheral neuropathy
hemoglobin a1c
diabetic peripheral neuropathy
  • 30 Nov, 2021
  • 29 locations